logo

Exclusive Market Insight

& Scientific analysis

subscribe today
  • Exclusive Posts
  • Industry Newsletters
  • Clinical Trials
  • Possible Takeovers
  • Technology of the Week
  • Stock Table
  • Therapeutic Vaccines
  • Development-Stage Firms
  • Genomics
  • Prohost Picks
  • And much more...
Trick or TradeToday’s HighlightsProhost LettersNews & CommentsImpacting NewsContact
Login

Category: Impacting News

GlaxoSmithKline and Vir Biotechnology Announce EUA from the US FDA for Sotrovimab in Treating Mild-to-Moderate COVID-19

GlaxoSmithKline and Vir Biotechnology are Granted an EUA for Sotrovimab GlaxoSmithKline ( GSK ) and Vir Biotechnology ( VIR ) announced the U.S. FDA has granted an Emergency Use Authorization ( EUA ) for sotrovimab (formerly VIR-7831) - an investigational...

Read More

May 27, 2021

0

Amgen: FDA Approves LUMAKRAS™, the First and Only Targeted Treatment for Patients with KRAS G12C-Mutated Locally Advanced or Metastatic NSCLC

Amgen Announced FDA Approval of LUMAKRAS ™   Amgen ( AMGN ) announced the news about the FDA approval of LUMAKRAS™ (sotorasib) on May 28, 2021. The firm indicated that the FDA granted approval is for adults with KRAS G12C-mutated locally...

Read More

May 31, 2021

0

Why Merck KGaA, Darmstadt, Germany Paid Sutro Biopharma. See Also: BMY Approval of Zeposia for UC

Sutro Biopharma Receives Milestone Payment from Merck KGaA, Darmstadt, Germany Sutro Biopharma ( STRO ) announced that it has received a milestone payment under its collaboration and license agreement with the healthcare division of Merck KGaA, Darmstadt,Germany . The payment...

Read More

June 1, 2021

0

The FDA Approved KemPharm Inc's AZSTARYS™ for ADHD

KemPharm Inc KemPharm Inc ( KMPH ) - a specialty pharmaceutical focused on the discovery and development of proprietary prodrugs, announced that the U.S. Food and Drug Administration (FDA) has approved the New Drug Application (NDA) for AZSTARYS™ , a...

Read More

March 3, 2021

0

COVID-19 and the Stock Market

COVID-19 and the Stock Market The coronavirus that causes COVID-19  is the topic that swallowed all other topics this week. The virus is spreading to many countries around the world. Some media interpreted the CDC's warnings as being in direct...

Read More

February 27, 2020

0

Optimism: The Market is Rebounding and Biotech Firms Inspiring News

The Market Soared Being optimistic about the greatness of American scientific capability does not mean underestimating the coronavirus' ability to infect, devastate and threaten human lives. Today the market is rebounding from the fear that caused the stock market to...

Read More

March 2, 2020

0

Fighting COVID-19. See Also: Stocks Gains Following the Market's Rebounding

Treating and Preventing COVID-19 Treating COVID-19, Gilead Sciences With regard to treating patients with COVID-19 we believe the most expected product to be used during this virus' outbreak will be Gilead Sciences’ ( GILD ) product remdesivir . This product...

Read More

March 5, 2020

0

Gilead Sciences CAR-T Cell Yescarta Became the First and Only FDA Approved Treatment for Patients with Relapsed or Refractory Indolent Follicular Lymphoma

Gilead Sciences Yescarta for Relapsed or Refractory Indolent Follicula Lymphoma If Kite Pharma - a Gilead Sciences ( GILD ) company, had been acquired by any firm other than Gilead the stock would have gained at least 20% because of...

Read More

June 16, 2021

0

An FDA Approval for Blueprint Medicines. See Also: An Important Presentation from IVERIC Bio

Inferior ways used to evaluate clinical-stage biotech firms are those that ignore the sciences, the technologies and the promising results from the products in clinical trials. It reached a stage where assessors are even ignoring the value of the approval...

Read More

June 18, 2021

0

Auris Medical Holding Ltd has Encouraging Results Addressing the Unmet Needs of ATLL

Auris Medical Holding Ltd OligoPhore TM Technology for ATLL Auris Medical Holding Ltd. ( EARS ) is a company focusing on addressing unmet medical needs through RNA therapeutics for allergies, viral infection protection and inner ear therapeutics. The firm has...

Read More

June 21, 2021

0

  • Previous
  • 1
  • 2
  • ...
  • 19
  • 20
  • 21
  • ...
  • 76
  • 77
  • Next

Search ProhostBiotech

Popular Links

23andMe Holding Co (ME)Abbott Laboratories (ABT)AbbVie Inc (ABBV)AbCelleraAbeona Therapeutics (ABEO)Ablynx (ABLX)AbVitro IncAcadia (ACAD)Acceleron Pharma (XLRN)AcelRx Pharmaceuticals (ACRX).Acorda Therapeutics Inc (ACOR)Acumen Pharmaceuticals (ABOS)AdaptImmune Therapeutics (ADAP)Adaptive BiotechnologiesADC Therapeutics (ADCT)Adimab LLCAdvanced Micro Devices (AMD)Advaxis (ADXS)Adverum Biotechnologies (ADVM)Aerie Pharmaceuticals (AERI)AgenTus TherapeuticsAgenus (AGEN)AgeX Therapeutics (AGE)Agilent Technologies (A)Agilis Biotherapeutics IncAgios Pharmaceuticals (AGIO)AIM ImmunoTech (AIM)Aimmune Therapeutics (AIMT)Akari Therapeutics (AKTX)Akashi TherapeuticsAkcea Therapeutics (AKCA)Akebia Therapeutics Inc (AKBA)Akero Therapeutics (AKRO)Akous Inc (a wholly owned subsidiary of Eli Lilly Company)Alder BioPharmaceuticals (ALDR)Alexion Pharmaceuticals (ALXN)Alkermes (ALKS)Allergan Plc (AGN)Allogene TherapeuticsAllogene Therapeutics (ALLO)

Recent

AstraZeneca Product Fasenra Approved in the US for Eosinophilic Granulomatosis with Polyangiitis 

September 19, 2024

0

The U.S. FDA Approves Novartis' Kisqali® to Reduce the Risk of Recurrence in People with HR+/HER2- Early Breast Cancer

September 18, 2024

0

AstraZeneca’s Imfinzi + Imjudo Demonstrated Unprecedented Overall Survival in Advanced Liver Cancer

September 17, 2024

0

Halozyme Therapeutics Announced FDA Approval of Roche’s Tecentriq Hybreza with ENHANZE

September 13, 2024

0

Johnson & Johnson Product TREMFYA® Receives U.S. FDA Approval

September 12, 2024

0

Prohost Biotech – Exclusive Biotech Research Copyright © 2026.
Privacy Policy